A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes
Open Access
- 1 October 1999
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 44 (4), 525-531
- https://doi.org/10.1093/jac/44.4.525
Abstract
Valaciclovir is a prodrug of acyclovir with more favourable bioavailability. Twice daily oral administration of valacyclovir is recommended in patients with genital herpes. A double-blind, randomized, controlled, multicriteria equivalence trial was conducted to determine whether od treatment with valacyclovir 1000 mg is as effective as bd treatment with 500 mg in patients with recurrent genital herpes. A total of 922 immunocompetent outpatients were treated with either regimen for 5 days; treatment was self-initiated at the first symptoms of the next recurrence. The principal outcome measures were the percentage of lesions healed at day 6, time to healing, time to cessation of pain, discomfort or itching, the percentage of abortive episodes and safety. Equivalence was assessed by comparison of 80% confidence limits for each measure; the two regimens were regarded as equivalent if the lower confidence limit was higher than a pre-determined equivalence limit calculated to show a maximum 10% inferiority of valacyclovir 1000 mg od against valaciclovir 500 mg bd. Intention-to-treat analysis showed that the two treatments were equivalent for each outcome measure. Hence, it is concluded that valacyclovir 1000 mg od is as effective as 500 mg bd as self-initiated therapy in patients with recurrent genital herpes.Keywords
This publication has 14 references indexed in Scilit:
- A Randomized, Placebo-Controlled Comparison of Oral Valacyclovir and Acyclovir in Immunocompetent Patients With Recurrent Genital Herpes InfectionsArchives of Dermatology, 1998
- Herpes Simplex Virus Type 2 in the United States, 1976 to 1994New England Journal of Medicine, 1997
- ValaciclovirDrugs, 1996
- A Large-Scale, Placebo-Controlled, Dose-Ranging Trial of Peroral Valaciclovir for Episodic Treatment of Recurrent Herpes GenitalisArchives of Internal Medicine, 1996
- Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteersCancer Cell, 1993
- Acyclovir: A Decade LaterNew England Journal of Medicine, 1992
- Herpes Simplex Virus Infection as a Risk Factor for Human Immunodeficiency Virus Infection in HeterosexualsThe Journal of Infectious Diseases, 1992
- AcyclovirDrugs, 1989
- Metabolism of acyclovir in virus-infected and uninfected cellsAntimicrobial Agents and Chemotherapy, 1981
- Risk of Recurrence after First Episodes of Genital HerpesNew England Journal of Medicine, 1981